BRPI0921156A2 - inibidores de pi3k/mtor quinase - Google Patents

inibidores de pi3k/mtor quinase

Info

Publication number
BRPI0921156A2
BRPI0921156A2 BRPI0921156A BRPI0921156A BRPI0921156A2 BR PI0921156 A2 BRPI0921156 A2 BR PI0921156A2 BR PI0921156 A BRPI0921156 A BR PI0921156A BR PI0921156 A BRPI0921156 A BR PI0921156A BR PI0921156 A2 BRPI0921156 A2 BR PI0921156A2
Authority
BR
Brazil
Prior art keywords
pi3k
kinase inhibitors
mtor kinase
mtor
inhibitors
Prior art date
Application number
BRPI0921156A
Other languages
English (en)
Inventor
Congxin Llang
Zhigang Lin
Original Assignee
Xcovery Holding Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xcovery Holding Co Llc filed Critical Xcovery Holding Co Llc
Publication of BRPI0921156A2 publication Critical patent/BRPI0921156A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0921156A 2008-11-11 2009-11-11 inibidores de pi3k/mtor quinase BRPI0921156A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19901908P 2008-11-11 2008-11-11
US21482809P 2009-04-28 2009-04-28
PCT/US2009/006071 WO2010056320A2 (en) 2008-11-11 2009-11-11 Pi3k/mtor kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0921156A2 true BRPI0921156A2 (pt) 2016-02-23

Family

ID=42170586

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921156A BRPI0921156A2 (pt) 2008-11-11 2009-11-11 inibidores de pi3k/mtor quinase

Country Status (10)

Country Link
US (1) US8586582B2 (pt)
EP (1) EP2382207B1 (pt)
JP (1) JP5877064B2 (pt)
KR (1) KR20110098908A (pt)
CN (1) CN102264732A (pt)
AU (1) AU2009314544C1 (pt)
BR (1) BRPI0921156A2 (pt)
CA (1) CA2743015A1 (pt)
ES (1) ES2539478T3 (pt)
WO (1) WO2010056320A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
JP2013505965A (ja) * 2009-09-29 2013-02-21 エックスカバリー ホールディング カンパニー エルエルシー Ｐｉ３ｋ（デルタ）選択的阻害剤
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
JP2013529212A (ja) * 2010-05-19 2013-07-18 エクスカバリー ホールディング カンパニー，エルエルシー ｍＴＯＲ選択的キナーゼ阻害剤
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
MX343706B (es) * 2011-01-31 2016-11-18 Novartis Ag Derivados heterocíclicos novedosos.
WO2012136622A1 (en) 2011-04-04 2012-10-11 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
FR2986232B1 (fr) * 2012-01-26 2014-02-14 Sanofi Sa Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
WO2013138860A1 (en) * 2012-03-22 2013-09-26 Biota Europe Limited Antibacterial compounds
CN103374021B (zh) * 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
WO2014072937A1 (en) 2012-11-08 2014-05-15 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
EP2733143A1 (en) 2012-11-14 2014-05-21 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma receptors ligands
CN104557872B (zh) 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
WO2015155624A1 (en) * 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
KR102678538B1 (ko) 2015-10-02 2024-06-28 센티넬 온콜로지 리미티드 P70s6 키나제 억제제로서의 2-아미노퀴나졸린 유도체
EP4681774A3 (en) 2021-03-29 2026-03-25 Gilead Sciences, Inc. Khk inhibitors
TW202602891A (zh) * 2024-03-28 2026-01-16 大陸商勵締（杭州）醫藥科技有限公司 具有mTOR抑制活性的有機化合物及其用途
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2150941T3 (es) * 1992-04-03 2000-12-16 Upjohn Co Aminas biciclicas-heterociclicas eficaces farmaceuticamente.
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US8763081B2 (en) * 2006-04-03 2014-06-24 Bridgeport Networks, Inc. Network based authentication
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
EP2050749B1 (en) * 2006-08-08 2017-11-22 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as pi3k inhibitor and use thereof
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
EP2209786B1 (en) * 2007-10-05 2013-02-27 Verastem, Inc. Pyrimidine substituted purine derivatives
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate

Also Published As

Publication number Publication date
KR20110098908A (ko) 2011-09-02
EP2382207B1 (en) 2015-04-29
AU2009314544A1 (en) 2010-05-20
EP2382207A2 (en) 2011-11-02
WO2010056320A3 (en) 2010-09-16
US20110281857A1 (en) 2011-11-17
CN102264732A (zh) 2011-11-30
EP2382207A4 (en) 2012-09-12
US8586582B2 (en) 2013-11-19
WO2010056320A2 (en) 2010-05-20
JP5877064B2 (ja) 2016-03-02
CA2743015A1 (en) 2010-05-20
ES2539478T3 (es) 2015-07-01
AU2009314544C1 (en) 2015-11-12
JP2012508236A (ja) 2012-04-05
AU2009314544B2 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
BRPI0921156A2 (pt) inibidores de pi3k/mtor quinase
IL280173A (en) Inhibitors of brutons tyrosine kinase
CY2020023I1 (el) Αναστολεiς βητα-λακταμασων
CY2019027I1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY2019009I2 (el) Αναστολεις πρωτεϊνικων κινασων
BRPI0811434A2 (pt) imidazopiridazinas como inibidores de pi3k lipídeo cinase.
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI0908494A2 (pt) Inibidores de pirrolopirazina quinase
ATE519763T1 (de) Pyrrolopyrazin-kinasehemmer
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI0910668A2 (pt) inibidores de proteína quinases
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0918846A2 (pt) inibidores de cinase heterocíclica
BRPI0807893A2 (pt) Imidazoquinolinas como inibidores duais de lipídio quinase e mtor.
EP2498607A4 (en) Kinase Inhibitors
EP2493313A4 (en) Kinase Inhibitors
BRPI0916295A2 (pt) inibidores de pirazolopiridina tricíclica cinase
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
BRPI1009112A2 (pt) inibidores de tirosina quinase de bruton
BRPI0922880A2 (pt) compostos inibidores de quinase
BRPI0716781A2 (pt) Inibidores da quinase
EP2558099A4 (en) Kinase inhibitors
BRPI0717928A2 (pt) Imidazopiridazinas como inibidores da cinase de lipídio pi3k
BRPI0912475A8 (pt) compostos como inibidores de quinase
BRPI0918564A2 (pt) inibidores

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]